PCSK9 inhibitors chosen as rapid uptake products by the AAC

24 October 2018

The UK Secretary of State for Health and Social Care has announced that the PCSK9 inhibitor class has been selected as a treatment that needs to see a rapid increase in uptake to ensure that patients, and the National Health Service (NHS), get the benefits of this class of medicines.

Increasing the uptake of PCSK9 inhibitors in patients with high lipid levels, including those with primary familial hypercholesterolemia and mixed dyslipidemia who maybe at high-risk of cardiovascular disease may help reduce their low-density lipoprotein (LDL) concentrations towards recommended levels. Raised LDL levels are a risk factor for cardiovascular disease. The National Institute for Health and Care Excellence (NICE) believed there would be a relevant benefit both to patients and also to the NHS.

The Accelerated Access Collaborative (AAC) was announced in November 2017, following the government’s Accelerated Access Review (AAR), with the aim of getting breakthrough products to market, and then to patients, as quickly as possible.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK